Supplements · Sweeteners · Diets · Metabolic & Cardiometabolic
allulose decreases postprandial glucose
In plain terms: Does allulose lower blood sugar after a meal?
Leans support Supplements 💰 Industry COI noted🔬 Includes disconfirming
Part of: 🧪 allulose
RefutedContestedStrong support
consensus score 0.56
Yes, but the effect is modest and works best when eaten alongside sugary food.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
6 support 0 contradict 3 tested null 1 mixed · 10 sources, 6 independent groups · 4 superseded — pooled inside a review, counted once
What the evidence shows
Small doses of allulose (~5-10 g) blunt the postprandial glucose and insulin response to a co-ingested carbohydrate (especially sucrose) - the strongest, most replicated allulose finding. Acute and modest; best demonstrated with sugar co-ingestion. The lead lever for a sweetened functional bread.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Buranapin S et al] # corrected 2026-08-17 from PubMed; was [(Thai crossover) 2024 · (RCT) | RCT | supports | moderate | n=30 dose-response RCT: allulose+sucrose lowered peak glucose & insulin dose-dependently ↩ SUPERSEDED — pooled in the review above, counted once |
| Osborn 2026 2026 · Am J Clin Nutr | meta-analysis | supports | high | SR/MA of controlled human trials: allulose (and tagatose) blunt postprandial glucose; cardiometabolic effects summarized. |
| d10-24875-gmm-m26001086 2026 · Gaceta Médica de México | meta-analysis | mixed | high | Meta-analysis of 12 RCTs (humans) on allulose and glucose parameters. Allulose significantly reduced plasma glucose iAUC in both high- and low-GI control-meal subgroups, and reduced absolute plasma glucose in the high-GI subgroup, but had n |
| Teysseire F et al 2023 · study_type: RCT | RCT | supports | moderate | n=18 healthy subjects, randomized double-blind crossover; 25g D-allulose vs water vs 50g erythritol. Glucose and insulin concentrations lower after D-allulose vs water (p=0.001, p=0.005), but Bayesian reanalysis showed no difference for ins |
| Franchi 2021 · BMJ Open Diabetes Res Care | RCT | supports | moderate | D-allulose added to 75g sucrose load lowered glucose & insulin response in Western adults; crossover. ↩ SUPERSEDED — pooled in the review above, counted once |
| Braunstein 2018 · Nutrients | RCT | tested-null | moderate | FACE trial: small catalytic allulose doses failed to reduce glucose iAUC after 75g-OGTT in healthy adults. |
| Tak 2023 · Nutr Res Pract | observational | tested-null | low | Diabetes-specific ONS containing allulose improved glycemic profiles & weight in overweight/obese T2D over the comparator. |
| Han Y, et al. 2018 · Nutrients | RCT | tested-null | moderate | Dose-dependent allulose reduced body fat in adults but did not change fasting glucose/lipids; weight not glucose endpoint. |
| Fukunaga K et al] # corrected 2026-08-17 from PubMed; was [(T2D CGM crossover) 2023 · (RCT) | RCT | supports | moderate | T2D CGM crossover: 8.5g allulose in a meal lowered peak glucose & insulin demand ↩ SUPERSEDED — pooled in the review above, counted once |
| Lee 2025 · Antioxid Redox Signal | animal | supports | moderate | OFF-SCOPE, zero weight — a real finding filed against the wrong outcome. The paper's own statement of what it measured: 'It focuses on the impact of D-allulose on adipocyte differentiation and obesity in high-fat diet (HFD)-administered and GLP-1R knockout (KO) mice over 12 weeks.' Its in-vivo result is adiposity, not glycemia: 'Furthermore, in vivo studies revealed that D-allulose administration significantly regulated body weight and other obesity parameters in HFD-fed mice', with the effect requiring the receptor — 'However, these effects were not observed in GLP-1R KO mice, suggesting that the antiobesity effects of D-allulose rely on the presence of GLP-1R.' The mechanism is receptor-stability, not glucose handling: 'D-allulose effectively regulated adipocyte differentiation by inhibiting the NADP+/NADPH-ROS-inositol-requiring enzyme 1a (IRE1a)-regulated IRE1-dependent decay (RIDD) axis, resulting in controlled decay of GLP-1R, a newly identified RIDD target.' THE PRIOR EXTRACT INVENTED THE OBJECT: it read 'regulates obesity/glucose'; the paper says obesity, and the '/glucose' was the appraiser's addition — the sole basis on which this row voted on an acute postprandial-glycemia claim whose scope is co-ingestion with sucrose. ABSENCE IS NOT A FINDING: I am not asserting no glucose was measured. Full text is unobtainable (no PMCID; Europe PMC isOpenAccess:N), so any Results-level glycemic endpoint is cannot-tell — and a chronic 12-week glucose-tolerance improvement would still sit outside this claim's acute co-ingestion scope. Grade and quality left unchanged as moot at zero weight, though note the sibling row on this same paper grades it in-vitro while this one grades it animal; the paper is both (cell work plus a 12-week mouse experiment), and the source note's study_type: in-vitro is the root of that split. COI VISIBLE IN THE AUTHOR BLOCK (flag, not acted on): '(5)Food Biotech R&D Center, Samyang Corp., Seongnam-si, Republic of Korea.' — the allulose manufacturer, whose COI is already flagged on ev-s42280385, a row that votes on this same claim. No funding statement is recoverable from the abstract. |
| Braunstein CR et al] # corrected 2026-08-17 from PubMed; was [(Sievenpiper group) 2020 · Clin Nutr | meta-analysis | supports | moderate | MA of controlled feeding trials: catalytic fructose-epimer (incl. allulose) doses lowered postprandial glucose to a carb load |
| Ahmed A et al 2022 · study_type: observational | observational | supports | moderate | Systematic search (50 human studies) of rare sugars including allulose; narrative synthesis (explicitly no formal quality assessment or quantitative pooling) concludes rare sugars offer short- and long-term glycemic control benefits, effect |
| Noh 2026 · Nutrients | RCT | supports | low | Low-digestible carbohydrates incl. allulose differentially modulated postprandial glucose/incretin/satiety in humans; exploratory. |
| Japar S et al 2022 · study_type: observational | observational | supports | low | n=12 T2DM adults, single-arm pilot (5-day control vs 5-day 8.5g D-allulose before iftar during Ramadan), CGM-measured. Postprandial peak glucose and iAUC (0-180min) significantly lower during allulose consumption period vs control. |
| Noronha 2018 · Diabetes Obes Metab | RCT | supports | high | Small catalytic doses (5-10g) of allulose did not significantly lower postprandial glucose iAUC in T2D; underpowered equivalence. ↩ SUPERSEDED — pooled in the review above, counted once |
| Ohbayashi 2026 · Diabetes | animal | supports | moderate | D-allulose-induced intestinal GLP-1 cooperates with insulin via vagal afferents to lower blood glucose in mice (mechanism). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.